natgillin/translations-raw huggingface dataset:
Onychoschizia and ungual brittleness is a widespread condition that affects mainly housewives, workmen and workwomen, dressmakers, nurses, but also employees. 
Listanje nokta i ungualna lomljivost je često prisutno stanje koje pogađa mnoge kućanice, radnike i radnice, švelje, medicinske sestre, ali i zaposlenike.
Rapamycin is unstable in solution; it degrades in plasma and in low and neutral pH buffers at 37°C with a half-life of less than 10 hours. 
Rapamicin je u otopini nestabilan; razgrađuje se u plazmi i u puferima niskog i neutralnog pH pri 37 *C s poluživotom manjim od 10 sati.
the amino acid sequence selected from the group consisting of SEQ ID NOs 20 to 38, 58 to 76 and 77 to 95; 
(a) amino kiselinsku sekvencu izabranu iz skupine koja se sastoji od SEQ ID Br. 20 do 38, 58 do 76 1 77 do 95;
The cable fixture device according to claim 8, wherein the first fixture is mechanically jointed with the supporting portion. 
Spojna kutija za komunikacijski kabel (40, 50, 60, 80) prema zahtjevu 8, naznačena time da je prvi držač (93A, 98) mehanički spojen sa nosivim dijelom (93, 97).
An in vitro method for modifying a genome at a genomic locus of interest in a pluripotent cell, comprising: 
PATENTNI ZAHTJEVI 1. In vitro metoda za modifikaciju genoma na genomskom lokusu od interesa u stanici mišjeg embrionalnoj stem
A pharmaceutical composition for treating a wound comprising negatively charged polystyrene microspheres suspended in a hypotonic solution, wherein the hypotonic solution is water, the pharmaceutical composition further comprising a thickening agent, wherein the thickening agent forms a solution having a specific gravity in the range of 1.02 - 1.07 grams per cubic centimeter measured at 25°C similar to the specific gravity of the polystyrene microspheres. 
Farmaceutski pripravak za liječenje rane koji sadrži negativno nabijene polistirenske mikrosfere suspendirane u hipotoničnoj otopini, gdje je hipotonična otopina voda, pri čemu farmaceutski pripravak dodatno sadrži tvar za zgrušavanje, gdje tvar za zgrušavanje tvori otopinu koja ima specifičnu težinu u opsegu od 1.02 - 1.07 grama po kubnom centimetru izmjereno na 25%, slično specifičnoj težini polistirenskih mikrosfera.
A pharmaceutical composition which comprises an antiviral effective amount of one or more of the compounds as claimed in claim 1, together with one or more pharmaceutically acceptable carriers, excipients or diluents. An intermediate compound which is selected from the group of: 
Spoj prema bilo kojem od patentnih zahtjeva 1 do 12 ijedan ili više farmaceutski prihvatljivih nosača, ekscipijenata ili razblaživača, za uporabu u liječenju; poželjno za uporabu u liječenju sisavca inficiranog HIV virusom. 15. Intermedijerni spoj koji je izabran iz grupe koju čine:
inhibition of proliferation of a cell expressing CLDN6, 
inhibiciju proliferacije stanice koja eksprimira CLDN6,
The method of claim 4, wherein the aminooxy compound is chosen from compounds of Formula III: wherein Y is the second reactive group, n is chosen from integers ranging from 1 to 10, and P is chosen from amino protecting groups. 
reakciju aminooksi skupine oligosaharida s barem jednom karbonilnom skupinom proteina, te se tako spaja oligosaharid na protein, pri čemu oligosaharid je oligosaharid s Formulom IV: [image] pri čemu su m i p neovisno odabrani od cijelih brojeva u rasponu od 1 do 10.
The compound of claim 1 or a salt or polymorph thereof, wherein R3 is -C(O)-NH-Z3(R10); X3 is absent or lower alkylidene; Z3 is absent, -SO2- or alkyl (wherein alkyl is optionally substituted at one or more positions by halogen, hydroxy or carbonylalkoxy); and, R10 is hydrogen or C3-C12 cycloalkyl, wherein C3-C12 cycloalkyl is optionally substituted by one or more hydroxy, alkyl, alkoxy, carboxy, carbonylalkoxy or carbamoylalkyl. 
Spoj prema zahtjevu 1 ili njegova sol ili polimorf, naznačen time da R; je -C(O)-NH-Z;(Ri0); Xa je odsutan ili niži alkiliden; Z; je odsutan, ili alkil (pri čemu je alkil proizvoljno supstituiran u jednom ili više položaja sa halogenom, hidroksi ili karbonilalkoksi); i Ry je vodik ili C3-Cy> cikloalkil, pri čemu Cx3-C;> cikloalkil jo proizvoljno supstituiran sa jednim ili više hidroksi, alkilom, alkoksi, karboksi, karbonilalkoksi ili karbamoilalkilom.
Typically the Streptococcus pneumoniae vaccine in the vaccine kit of the present invention will comprise saccharide antigens (optionally conjugated), wherein the polysaccharides are derived from at least four serotypes of pneumococcus chosen from the group consisting of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F. 
Imunogeni pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što najmanje dva dodatna konjugata bakterijskih saharida sadrže saharid iz kapsule bakterije S. pneumoniae kojeg se dobiva iz soja kojeg se bira iz skupine koju čine serotipovi 1, 2, 3, 4, 5, 6A, 6B, TF, 8, 9N, 9V, 10A, IA, 12F, 14, 15B, I7F, 18C, 19A, 19F, 20, 22F, 23F 133F.
The organic phase was separated, washed with saturated sodium bicarbonate solution (10ml) dried via a frit and evaporated. 
Organsku fazu se odvoji, ispere zasićenom otopinom natrijevog bikarbonata (10 ml), osuši preko frite, te otpari.
A process for the preparation of a compound of the formula (15): by reacting a compound of the formula (14) with a Wittig reagent MePPh3Br in the presence of potassium tert-butoxide in THF. 
CBn Me (14) (15) reakcijom spoja formule (14) s Wittingovim reagensom MePPh;Br u prisutnosti kalij tert-butoksida u THF.
In the preferred embodiment of the machine 10, dose confirmation system 500 has a gantry 510 (similar to gantry 410 described above) with a pair of charge coupled device (CCD) cameras 520 that obtain images 525 of each of the carrier tablets 1000 . 
Uređaj (10) u skladu s patentnim zahtjevom 8, naznačen time što navedeni sustav za oblaganje (600) ima napravu za prskanje koja naprska navedena obloga (2300) na svaku od nosivih tableta (1000).
The device according to claim 1, wherein the perforated sheet is made of a plastic material. 
Uređaj sukladno zahtjevu 1, gdje je perforirani list izrađen od plastičnog materijala.
is selected from the group consisting of H, C1-C6alkyl optionally substituted with OH, NR11R11 or a 3-7 membered C1-C6heterocyclyl, -CO(C1-C6alkyl), optionally substituted C6-C10aryl, and optionally substituted C1-C9heteroaryl; 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je Q 3-10-eročlani C1-C9 heterociklil, supstituiran s di(C1-C6 alkil)amino-, gdje se navedeni 3-10-eročlani C1-C9 heterociklil bira iz skupine koju čine pirolidin i piperidin, ili njegova farmaceutski prihvatljiva sol.
The IL-17 antagonist for use according to claim 16, wherein the first treatment period ends within 30 days after disappearance of all symptoms of the AOID. 
IL-17 antagonist za uporabu u skladu sa zahtjevom 16, naznačen time, da prvo razdoblje liječenja završava unutar 30 dana nakon nestanka svih simptoma AQID.
In a preferred embodiment the compound of the present invention is intended for use as a medicament in the treatment of inflammation-associated pain, preferably arthritis, skin inflammation, inflammatory back pain, headache (including neurogenic migraine), inflammatory lesions of the central and peripheral nervous system (neuropathic pain), cancer pain, disorders of the immune system (HIV/AIDS, multiple sclerosis), traumatic pain, postoperative pain, inflamed joints, dental surgery, visceral pain, bone pain, burn injury and/or eye lesions. 
Spoj namijenjen upotrebi kao medikament u skladu s patentnim zahtjevom 7, naznačen time što se bol povezanu s upalom bira iz skupine koju čine artritis, upala kože, upalna bol u leđima, glavobolja, primjerice neurogena migrena, upalne lezije u središnjem i perifernom živčanom sustavu, primjerice neuropatska bol, bol uzrokovana rakom, poremećaji imunosnog sustava, primjerice HIV/AIDS ili multipla skleroza, traumatska bol, postoperativna bol, upaljeni zglobovi, kirurški zahvat na zubalu, visceralna bol, kostobolja, opeklinska ozljeda i lezije oka.
The organic phase was washed (3×50 ml) with a buffer solution Ph=4.2, dried over Na2SO4, filtered and concentrated under vacuum to obtain a yellow oil. 
Organska faza je prana (3 X 50 mL) s pufer otopinom pH = 4.2, sušena izand Na,SO4, filtrirana i uparena pod vakuumom i dobiveno je žuto ulje.
The solvent is removed, and the crude is used in the hydrolysis step. 
Otapalo se ukloni, a sirovi produkt upotrijebi u koraku hidrolize.
The use of (1,1-dioxo-1λ6-thiomorpholin-4-yl)-{6-[3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-pyridin-3-yl}-methanone or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of Alzheimer's disease. 
Spoj prema bilo kojem od zahtjeva 1 do 9, naznačen time, da spoj je (1,1-diokso-1λ6-tiomorfolin-4-il)-{6-[3-(4-fluoro-fenil)-5-metil-izoksazol-4-ilmetoksi]-piridin-3-il}-metanon ili njegova farmaceutski prihvatljiva sol.
1, where a block diagram of a GFCI 1 according to the present invention can be seen, the single-phase electrical power network or mains is indicated with 10; a hot wire 12 and a neutral wire 14, grounded, connect the network 10 to the separable contacts 22 a, 22 b of a relay 20 . 
Prema sl. 1, gdje je prikazan blok-dijagram GFCI-sklopa prema ovom izumu, jednofazni priključak na električnu mrežu ili izvodi označeni su s 10, fazni vod s 12, neutralni vod s 14, uzemljen i povezan s mrežom 10 preko odvojenih kontakata 22a, 22b na relej 20.
deformylating the compound of Formula XXXIV to give a compound of Formula XXXV, wherein 
Formuja XXXV i. deformilaciju spoja Formule XXXIV, čime se dobiva spoj Formule XXXV:
The isolated antibody or immunoreactive fragment thereof of any one of Items 1-2, wherein said antibody binds to B7-H3 that is internalized upon binding to B7-H3 expressed on the surface of a cancer cell. 
Molekula koja se veže na B7-H3 u skladu s patentnim zahtjevom 1 ili 2, naznačena time što se navedena molekula koja se veže na B7-H3 veže na B7-H3 koji se endogeno eksprimira na površini stanice raka.
is selected from optionally substituted cycloalkyl, CN, C(R12)═NOR18, and C(═O)N(R18)2, wherein said optional substituents are one to three R10 groups; 
R" je odabran od proizvoljno supstituiranog C3-C;g cikloalkila, CN, C(R')=NOR', te C(=0)N(R'*),, pri čemu su navedeni nezavisni supstituenti jedna do tri R'" skupine;
General features of the base unit 3 and the base part 5 in this embodiment are similar to the embodiments as described above. 
Opće značajke osnovne jedinice 3 i osnovnog dijela 5 u ovoj izvedbi su iste kao u gore opisanim izvedbama.
An isolated human antibody, or antigen-binding fragment thereof, capable of recognizing and binding to an epitope in the HA2 subunit of the influenza haemagglutinin protein (HA), characterized in that said antibody or antigen-binding fragment thereof has neutralizing activity against an influenza virus comprising HA of the H5 subtype, such as H5N1, H5N2, H5N8, and H5N9, and in that the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acids 1-121 of SEQ ID NO: 65, and a light chain variable region comprising the amino acids 1-112 of SEQ ID NO: 91. 
Izolirano ljudsko antitijelo, ili njegov dio koji veže antigen, koje je sposobno za prepoznavanje i vezanje na epitop u podjedinici HA2 hemaglutinin proteina influence (HA), naznačeni time da navedeno antitijelo ili njegov dio koji veže antigen ima neutralizirajuću aktivnost protiv virusa influence koji sadrži HA podvrste H5, kao što su H5N1, H5N2, H5N8, i H5N9, te time da antitijelo ili njegov dio koji veže antigen sadrži varijabilno područje teškog lanca koje sadrži aminokiseline 1-121 iz SEQ ID NO: 65, i varijabilno područje lakog lanca koje sadrži aminokiseline 1-112 iz SEQ ID NO: 91.
converting compound 9 to the structure and modifying compound 10 to yield the compound and reacting compound 11 to produce the compound and 
(1) konverziju spoja 9 do strukture i (3) modifikaciju spoja 10 da se proizvede spoj i
The tablet of any one of claims 1-13 and 15-16 that further comprises a film coating which preferably comprises 34 ± 12 mg of Opadry II Purple 33G100000. 
Tableta bilo kojeg od zahtjeva 1-13 i 15-16 koja dalje sadrži film omotač koji poželjno sadrži 34 + 12 mg Opadry II Purple 336100000.
A laminated acoustic building panel as claimed in claim 1 or claim 2, in which the adhesive has a dynamic Young's modulus (at 20° C.) of 0.1 to 0.5 MPa at 100 Hz and/or 0.5 MPa to 100 MPa at 1000 Hz and a loss factor of at least 50% (n>0.5). 
Laminirana akustična građevinska ploča prema zahtjevu 1 ili zahtjevu 2, naznačena time da ljepilo ima dinamički Youngov modul (kod 20%) od 0.1 do 0.5 MPa kod 100 Hz i/ili 0.5 MPa do 100 MPa kod 1000 Hz i faktor gubitka od barem 50% (1 > 0.5).
The immunogenic composition of any preceding claim wherein the Hib saccharide is conjugated to a carrier protein selected from the group consisting of TT, DT. CRM197, fragment C of TT, protein D, OMPC and pneumolysin. 
Imunogeni pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što saharid Hib je konjugiran s proteinom-nosačem, kojeg se bira iz skupine koju čine TT, DT, CRM197, fragment C od TT, protein D, OMPC i pneumolizin.
Polymorphs may also be obtained by heating or melting a compound of formula I followed by gradual or fast cooling. 
Polimorfe se također može dobiti i HR P20070422 T3 grijajnjem ili taljenjem spoja formule I, te postupnim ili brzim hlađenjem.
The process according to any one of the preceding claims, characterised in that activated carbon is additionally added to the aqueous medium, preferably prior to the addition of surface-reacted calcium carbonate. 
Postupak prema zahtjevu 15, naznačen time da se aktivni ugljik dodaje u vodeni medij prije dodavanja površinski reaktivnog kalcijevog karbonata.
The composition of claim 1, wherein the at least one solvent of the liquid injection is selected from propanediol, ethanol, polyethylene glycol 400, polyethylene glycol 200, glycerol, and water. 
Injekcija prema patentnom zahtjevu 1 ili 2, gdje je otapalo tekućinske injekcije izabrano iz skupine koja se sastoji od propandiola, etanola, polietilen glikola 400, polietilen glikola 200, glicerola, vode i njihovih smjesa.
Example 2 Large-Scale Industrial Synthesis of the Compound of Formula 1 (in the Form of the Para-Toluenesulphonate Acid Addition Salt) 
Ka po izboru u obliku njegovih kiselinskih adicijskih soli, naznačen time, da u prvom koraku diamin formule 2 1
Phosphatidylcholine for use in the method of claim 7, wherein administration results in a quality of life index score improvement of at least 25%, or wherein administration results in a histology index reduction of at least 25%, or wherein administration results in an endoscopic activity index improvement of at least 50%, or wherein administration results in a clinical activity index improvement of at least 50%, or wherein administration results in cessation of clinically active ulcerative colitis. Phosphatidylcholine for use in a method of ameliorating at least one symptom of ulcerative colitis comprising: identifying an individual having steroid-refractory ulcerative colitis; and 
Fosfatdilkolin za uporabu u postupku prema zahtjevu 7, naznačen time, da se rezultati primjene očituju u boljoj kvaliteti života gdje je indeks postignutog poboljšanja barem 25%, ili pri čemu su rezultati primjene takvi da je indeks histološkog smanjenja najmanje 25%, ili pri čemu su rezultati primjene takvi da je indeks poboljšanja endoskopske aktivnosti najmanje 50%, ili pri čemu su rezultati primjene takvi da je indeks poboljšanja kliničke aktivnosti najmanje 50%, ili pri čemu su rezultati primjene takvi da se očituje prestanak kliničke aktivnosti ulcerativnog kolitisa.
The blister pack according to Claim 19, in which said second layer (8B) is covered with a paint layer (8C). 
Blister pakiranje prema 17. zahtjevu, naznačeno time da navedeni drugi sloj (88) pokriven slojem boje (8c).
fuelling an engine with the biogas to produce energy and heat. 
)) punjenje motora bio gorivom dobivenim u koraku i) kako bi se proizvela energija i toplina.
The solid formulation according to any one of claims 1 to 14, characterized in that the solid formulation is a tablet and consists of 1.25 mg, 2.5 mg, 5 mg or 10 mg pimobendan, and further consists of lactose, corn starch, croscarmellose-sodium, citric acid, artificial beef flavor, polyvidone, colloidal anhydrous silica and magnesium stearate. 
Čvrsta formulacija prema bilo kojem od patentnih zahtjeva 1 do 15, naznačena time, da se kod čvrste formulacije radi o tableti koja se sastoji od 1,25 mg, 2,5 mg, 5 mg ili 10 mg pimobendana, te se nadalje sastoji od laktoze, kukuruznog škroba, natrijeve kroskarmeloze, bezvodne limunske kiseline, umjetne arome govedine, polividona, koloidnog bezvodnog silicijevog dioksida i magnezijevog stearata.
Figures 2 and 3 show detailed diagrams of parts of the Figure 1 device. 
prikazuju detaljne dijagrame dijelova naprave sa Slike 1.
Method as claimed in any of the foregoing claims, characterized in that the road comprises a number of lanes, on each of which a specific point is to be monitored, and for each lane a radar beam is transmitted at a related angle from the transmitting and receiving location. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time što prometnica (2) sadrži veći broj traka (8L, 8R), na svakoj od kojih treba pratiti određenu točku, te se za svaku traku (8L, 8R) radarski snop (5L, 5R) se prenosi pod odgovarajućim kutom od mjesta prenošenja i prijema.
Alternatively, the component-holder plate, provided with the relevant finishing plate, can be moved forward and held flush with the front opening of the box-shaped collar by means of a spacing frame located between the plate and the other tubular threaded elements of the collar. 
Alternativno se može ploča za nošenje komponenti, koja je snabdjevena s odgovarajućom završnom pločom, pomaknuti prema naprijed i držati poravnana s prednjim otvorom okvira koji ima oblik kutije pomoću okvira za održavanje odstojanja koji je smješten između ploče i drugih cijevnih elemenata okvira, pri čemu ovi cijevni elementi imaju navoj.
The liquid 4 may be pressurized by a liquefied gas or compressed gas or by any suitable biasing means or any other means. 
Tekućina 4 može biti stlačena pomoću ukapljenog plina ili komprimiranog plina ili pomoću bilo kojeg prikladnog sredstva za prenaprezanje ili bilo kojeg drugog sredstva.
The process comprises crystallization of asenapine maleate by cooling from an ethanol/water mixture containing dissolved asenapine maleate. 
Postupak obuhvaća kristalizaciju asenapin maleata putem hlađenja iz smjese etanol/voda koja sadrži otopljen asenapin maleat.
Ra3 is selected from selected from hydrogen, methoxy, unsubstituted C1-C6 alkyl, halogen, and 
Ra; je odabran od sljedećih: vodik, metoksi, nesupstituirani C,-Cg alkil, halogen i
compressing the blend from the step (6) into tablets; and 
komprimiranja smjese iz (5) u tablete;
the donor sequence is introduced to the cell using a viral vector, as an oligonucleotide or on a plasmid; 
(a) donorska sekvenca se uvodi u stanicu upotrebom virusnog vektora, kao oligonukleotid ili u okviru plazmida;
The receiver has outputs that become active when corresponding signals from the transmitter are received. 
Prijemnik ima izlaze koji postaju aktivni kad se primi odgovarajući signal s odašiljača.
The process of claim 7, further comprising adding a suspension comprising gelatin in a non-hydrated form to the boiled first mixture. 
Proces iz patentnog zahtjeva 6, koji dalje sadrži dodavanje suspenzije koja sadrži želatinu u ne-hidratiziranom obliku u prokuhanu prvu smjesu.
emulsifying said antigen/adjuvant/oil component mixture of (b) to form a water-in-oil emulsion, thereby forming a vaccine composition. 
(c) emulgiranju navedene smjese antigen/adjuvans/uljna komponenta iz (b) kako bi se dobilo emulziju vode u ulju, čime je načinjen cjepivni pripravak.
A pyrazole compound represented by the formula (I) or its salt: 
"Spoj pirazola predstavljenog formulom (I) ili njegova sol: naznačen time, da
The polypeptide of claim 1 or 2, wherein the polypeptide linker comprises any one of SEQ ID NOs: 63-65. 
Polipeptid iz patentnog zahtjeva 1 ili 2, gdje polipetidni linker sadrži SEQ ID NO: 84.
A compound, or a pharmaceutically acceptable salt thereof, of claims 1-8, or a pharmaceutical composition of claim 9 or claim 10, for use according to claim 1, wherein the disorder is cancer is selected from leukemia, lymphoma, thymus, brain, lung, squamous cell, skin, eye, retinoblastoma, intraocular melanoma, oral cavity and oropharyngeal, bladder, gastric, stomach, pancreatic, bladder, breast, cervical, head, neck, renal, kidney, liver, ovarian, prostate, colorectal, esophageal, testicular, gynecological, thyroid, CNS, PNS, AIDS-related cancer, Kaposi's Sarcoma, mastocytosis, and viral-induced cancer. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, ili njegova farmaceutski prihvatljiva sol, ili farmaceutski pripravak u skladu s patentnim zahtjevom 4, namijenjeni upotrebi u skladu s patentnim zahtjevom 7, naznačeni time što se rak bira između raka timusa, mozga, pluća, pločastih stanica, kože, oka, retinoblastoma, intraokularnog melanoma, raka usne šupljine i orofarinksa, mokraćnog mjehura, želučanog raka, raka želuca, gušterače, mokraćnog mjehura, dojke, vrata maternice, glave, vrata, bubrežnog raka, raka bubreg, jetre, jajnika, prostate, kolorektalnog raka, raka jednjaka, testisa, ginekološkog raka, raka štitnjače, CNS-a, PNSa, raka povezanog s AIDS-om, Kaposijevog sarkoma i raka uzrokovanog virusima.
Hemostatic composite comprising a haemostatic material and a single hydrophilic polymeric crosslinker, said crosslinker having electrophilic reactive groups, said composite comprising pores which allow external fluids, especially human blood, to access into said composite, wherein said haemostatic material is a non-woven or woven fabric of a haemostatic fiber. 
Hemostatski kompozit koji se uglavnom sastoji od hemostatskog materijala i jednog hidrofilnog polimernog sredstva za umrežavanje s elektrofilnim reaktivnim skupinama, te navedeni kompozit sadrži pore koje omogućavaju da vanjski fluidi, naročito ljudska krv, ulaze u navedeni kompozit, pri čemu navedeni hemostatski materijal je netkana ili tkana tkanina od hemostatskih vlakana.
The detailed examples are provided below. 
Detaljni primjeri dani su niže.
In a third aspect, the present invention relates to processes for preparing the compounds of formula (Ia) as depicted in the following reaction schemes: 
U trećem obliku, predloženi izum se odnosi na postupke za pripravu spojeva formula (Ia), kako je gore prikazana, u slijedećim reakcijskim shemama:
providing a solvent composition comprising methyl soyate, N- methylpyrrolidinone, an additional solvent, a diluent, and a cationic surfactant; 
osiguravanja da se formulacija otapala sastoji od metil-sojata, N-metilpirolidinona, dodatnog otapala, sredstva za raspršivanje i kationskog surfaktanta;
The solid oral dosage form according to any one of claims 1 to 7, wherein said solid oral dosage form comprises the compound in a concentration from 4% to 60% by weight of the composition. 
Čvrsti oralni dozni oblik prema zahtjevu 1, naznačen time, da oralni dozni oblik omogućava brzinu resorpcije kiseline bez valsartana, koja iznosi tmax od 1 do 2,2 sata nakon davanja jednostruke doze navedenog doznog oblika.
Similarly, the invention provides the use of a second pharmaceutical agent in the manufacture of a medicament, wherein the medicament is co-administered with IL-2 microaggregates of the invention. 
Slično, izum daje uporabu drugog farmaceutskog agensa u proizvodnji medikamenta, kod čega se medikament usporedno daje s IL-2 mikroagregatima iz izuma.
NCBI Number of access 14.5 9322 
(21) Broj predmeta: